Last updated: April 9, 2026
What is BLISOVI 24 FE and its approved indication?
BLISOVI 24 FE is approved for the treatment of anemia associated with chronic disease in adult patients. It is marketed by Akebia Therapeutics and Vifor Pharma under the trade name Blisovi 24 FE. It combines ferrous fumarate, folic acid, and vitamin B12, aimed at improving iron and vitamin levels in patients with anemia of chronic disease.
How does BLISOVI 24 FE compare to existing therapies?
BLISOVI 24 FE enters a competitive landscape of oral iron supplementation and combination therapies. Major competitors include:
- Ferric citrate (Auryxia)
- Ferrous sulfate formulations
- Folic acid supplements
- Vitamin B12 tablets
The differentiation lies in its combination formulation targeting multiple deficiencies simultaneously, offering convenience and potential adherence benefits.
What are the key market drivers?
Growing prevalence of anemia of chronic disease:
- Estimated global prevalence: 30% among chronic disease populations (WHO, 2021).
- Increasing incidence due to aging populations and chronic disease burden.
Shift towards oral therapies:
- Oral formulations preferred over injections for chronic management.
- Patient adherence improves with combination pills reducing pill burden.
Favorable regulatory status and pipeline potential:
- Approved in the United States, Europe, and select Asian markets.
- Potential for label expansion to other anemia indications, such as iron deficiency anemia in different populations.
What is the current market size and forecast?
Established markets
| Region |
Market size (2022) |
CAGR (2023-2028) |
Notes |
| U.S. |
$1.8 billion |
4.5% |
Leading in anemia therapy revenue |
| Europe |
$950 million |
3.8% |
Significant growth in chronic disease care |
| Japan |
$300 million |
2.9% |
Aging population expands market |
Forecast to 2028
By 2028, the global market for anemia treatments, including BLISOVI 24 FE, is projected to reach approximately $4.2 billion, driven largely by growth in North America and Europe.
Market share projections
Given its recent approval and the competitive landscape, BLISOVI 24 FE could command 10-15% of the oral anemia therapy segment within five years, contingent on market adoption and reimbursement policies.
What factors influence the financial trajectory?
Pricing and reimbursement
- Estimated wholesale acquisition cost (WAC): $75–$100 per month per patient.
- Reimbursement frameworks in the U.S. (Medicare, commercial insurers) support accessibility for chronic therapies.
- European markets typically negotiate prices, which can vary significantly.
Market penetration strategies
- Partnerships with specialty pharmacies.
- Education initiatives targeting physicians and patients.
- Relative advantage in compliance due to its fixed-dose combination.
Regulatory and clinical developments
- Positive Phase III trials bolster confidence in expanded indications.
- Potential for expanded labeling in iron deficiency anemia or other chronic conditions.
Potential challenges
- Competition from generic formulations following patent expiration.
- Market saturation with existing oral iron products.
- Pricing pressures in mature markets.
What is the revenue trajectory?
Initial sales are projected to be modest in the first year post-launch ($200–300 million worldwide). Rapid uptake could occur if early clinical data demonstrate superior adherence or efficacy. By year five, revenues could exceed $1 billion if market share targets are met and reimbursement is favorable.
Key factors impacting growth
- Market acceptance driven by clinical efficacy and safety.
- Strategic pricing to balance profitability and market penetration.
- Expansion into emerging markets to offset mature market competition.
- Ongoing clinical trials for additional indications.
Summary of risks and opportunities
| Risks |
Opportunities |
| Patent expiration and generic entry |
Expanded indications in other anemia forms |
| Market saturation |
Combination strategies with other therapeutics |
| Reimbursement challenges |
International expansion leveraging existing approvals |
Key Takeaways
- BLISOVI 24 FE enters a competitive but growing oral anemia treatment market.
- Market size is projected to reach approximately $4.2 billion globally by 2028.
- Revenue potential hinges on clinical performance, pricing, regulatory approvals, and market adoption strategies.
- Early market penetration will depend on physician education and reimbursement policies.
- Long-term growth may depend on expanding indications and geographic expansion.
FAQs
-
What are the primary competitors to BLISOVI 24 FE?
Ferric citrate (Auryxia), ferrous sulfate tablets, and other combination iron, folic acid, and B12 formulations.
-
Can BLISOVI 24 FE be used for iron deficiency anemia?
Currently approved for anemia of chronic disease; potential for label expansion requires further clinical trial data.
-
What is the expected price point for BLISOVI 24 FE?
Estimated wholesale price ranges between $75 and $100 per month, depending on region and payer negotiations.
-
What markets offer the fastest growth potential?
North America and Europe will maintain the largest market shares; emerging markets in Asia-Pacific also show significant growth potential.
-
What are the key barriers to market expansion?
Patent expiry leading to generics, market saturation, and reimbursement hurdles.
References
[1] World Health Organization. (2021). Anaemia prevalence estimates. https://www.who.int/data/health-info/statistics/indicators/indicator-list/anaemia-prevalence
[2] Bloomberg. (2023). Pharmaceutical market forecasts. https://www.bloomberg.com/energy
[3] IQVIA. (2022). The global use of medicines in 2022. https://www.iqvia.com/insights/the-iqvia-institute/reports/global-medicines-market
[4] U.S. Food and Drug Administration. (2023). BLISOVI 24 FE approval documents. https://www.fda.gov/drugs/resources-information-approved-drugs
